within Pharmacolibrary.Drugs.ATC.C;

model C03XA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0002466666666666667,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.1463,
    k12             = 27.6,
    k21             = 27.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03XA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Conivaptan is a non-selective vasopressin receptor antagonist used in the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. It blocks the action of antidiuretic hormone (ADH) at V1A and V2 receptors, promoting free water excretion without affecting sodium excretion. It is administered intravenously and is approved for short-term use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following intravenous infusion.</p><h4>References</h4><ol><li><p>Roy, MJ, et al., &amp; Keirns, JJ (2013). Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment. <i>Clinical pharmacokinetics</i> 52(5) 385–395. DOI:<a href=&quot;https://doi.org/10.1007/s40262-013-0047-8&quot;>10.1007/s40262-013-0047-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23456393/&quot;>https://pubmed.ncbi.nlm.nih.gov/23456393</a></p></li><li><p>Moen, MD, &amp; Keating, GM (2008). Intravenous conivaptan. <i>American journal of cardiovascular drugs : drugs, devices, and other interventions</i> 8(5) 341–349. DOI:<a href=&quot;https://doi.org/10.2165/00129784-200808050-00006&quot;>10.2165/00129784-200808050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18828645/&quot;>https://pubmed.ncbi.nlm.nih.gov/18828645</a></p></li><li><p>Marbury, T, et al., &amp; Pavliv, L (2017). Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. <i>Drug design, development and therapy</i> 11 373–382. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S125459&quot;>10.2147/DDDT.S125459</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28243060/&quot;>https://pubmed.ncbi.nlm.nih.gov/28243060</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03XA02;
